Alcohol use disorder affects millions of adults in the United States and remains one of the most persistent challenges in mental health care. The condition is marked by an inability to control drinking despite harmful consequences, and relapse rates remain high even with available treatments. Because of this, researchers continue to explore novel approaches that might reduce problematic alcohol use. Psychedelic substances have recently emerged as an area of interest, and a new analysis highlights an unexpected association involving LSD and alcohol use disorder.
How The Study Examined Psychedelics And Drinking Behavior
The findings come from an analysis of the National Survey on Drug Use and Health, a federally sponsored survey designed to represent the U.S. adult population. Researchers examined pooled data from 2021 through 2023, which included responses from more than 139,000 adults. Participants reported on substance use, mental health symptoms, and daily functioning.
To strengthen the analysis, the research team adjusted for factors that could influence both psychedelic use and alcohol problems. These included age, sex, income, education level, and use of other substances such as tobacco and cannabis. This approach allowed the investigators to better isolate the relationship between specific psychedelics and alcohol use disorder.
Recent LSD Use Shows A Unique Association
The most notable finding involved recent use of lysergic acid diethylamide, commonly known as LSD. Adults who reported using LSD within the past year were significantly less likely to meet diagnostic criteria for alcohol use disorder. After accounting for confounding factors, the analysis suggested roughly a 30 percent lower likelihood compared with individuals who did not report LSD use.
Among participants who did meet criteria for alcohol use disorder, those with recent LSD use also reported fewer symptoms. This suggests not only lower prevalence, but potentially reduced severity. Importantly, this pattern did not appear for other substances examined over the same time period.
Why Other Psychedelics Did Not Show The Same Pattern
The researchers also evaluated past year use of MDMA and ketamine. Neither substance showed a statistically significant association with alcohol use disorder. This raises the possibility that the observed relationship may be specific to LSD, or to the way LSD is typically used outside clinical settings.
When lifetime use was examined instead of recent use, the picture became more complicated. Individuals who had ever used psilocybin or MDMA were more likely to meet criteria for alcohol use disorder in the past year. In contrast, lifetime use of DMT was associated with lower odds of the disorder. These mixed results highlight how timing, context, and user characteristics can dramatically shape outcomes.
The Role Of Context And Psychological Change
One proposed explanation involves differences between clinical and recreational psychedelic use. In clinical trials, psychedelics are administered with careful preparation, therapeutic support, and structured integration. These elements are known to influence outcomes, especially in addiction treatment.
Outside clinical settings, experiences vary widely. Unsupervised psychedelic use can sometimes be distressing or destabilizing. In such cases, individuals may increase alcohol use to cope with lingering stress or anxiety. At the same time, some users report lasting psychological shifts after LSD experiences, including increased openness and reduced emotional rigidity. These changes could theoretically reduce motivations for heavy drinking in certain individuals.
What These Findings Mean For Interventional Psychiatry
This study does not establish causation. Because the data are cross sectional, it cannot determine whether LSD use leads to reduced drinking or whether individuals at lower risk for alcohol use disorder are simply more likely to use LSD. Self reported data also carry limitations, particularly for illegal substances.
Even so, the findings raise important questions for future research. Longitudinal studies that track individuals over time are needed to clarify directionality. Greater detail on dose, frequency, and setting will also be critical. For clinicians and researchers in interventional psychiatry, this work reinforces a key lesson: psychedelic outcomes are highly context dependent, and population level signals may differ sharply from clinical trial results.
Citations
Citation 1
Zech JM, Richard J, Jones GM. The relationship between psychedelic use and alcohol use disorder in a nationally representative sample. Journal of Psychoactive Drugs. 2024.
https://pubmed.ncbi.nlm.nih.gov/?term=Zech+psychedelic+alcohol+use+disorder
Citation 2
Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin assisted psychotherapy for alcohol use disorder. JAMA Psychiatry. 2022.
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2795625